Equillium (NASDAQ:EQ) Announces Quarterly Earnings Results

Equillium (NASDAQ:EQ) released its quarterly earnings results on Thursday. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.06, Zacks reports. The business had revenue of $4.39 million during the quarter. Equillium had a negative return on equity of 20.68% and a negative net margin of 10.05%.

Equillium Stock Performance

EQ traded down $0.08 during midday trading on Friday, hitting $0.41. The stock had a trading volume of 311,719 shares, compared to its average volume of 839,115. Equillium has a 1 year low of $0.37 and a 1 year high of $2.43. The business has a fifty day moving average of $0.76 and a 200 day moving average of $0.80. The company has a market cap of $14.53 million, a P/E ratio of -2.93 and a beta of 1.87.

Analyst Ratings Changes

Separately, Leerink Partners reaffirmed a “market perform” rating and set a $1.00 target price (down from $3.00) on shares of Equillium in a report on Friday.

About Equillium

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.